SavedAdd your journal

Journals / Turkish Journal of Pediatrics / 2018 / Cilt: 60 - Sayı: 3

Chelation therapy for secondary neonatal iron over load: Lessons learned from rhesus hemolytic disease

Fareed KHDAIR AHMAD
Tariq ALADILY
Olfat KHDAIR AHMAD
Eman F. BADRAN
Pages
335–339
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Treatmentresulted in marked reduction in ferritin level (down to 829 mg/L at the ageof 6 months), significant improvement in the liver enzymes, and resolutionof cholestasis

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Secondary neonatal iron overload occurs with intrauterine and post-natal bloodtransfusions.
📊
Key Findings & Data:Herein we report a case of a patient born at 36weeks of gestation, who had rhesus hemolytic disease.
💡
Conclusion & Impact:Treatmentresulted in marked reduction in ferritin level (down to 829 mg/L at the ageof 6 months), significant improvement in the liver enzymes, and resolutionof cholestasis
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Secondary neonatal iron overload occurs with intrauterine and post-natal bloodtransfusions. Treatment with intravenous Deferoxamine was reported only infour cases in the literature. Herein we report a case of a patient born at 36weeks of gestation, who had rhesus hemolytic disease. He developed secondaryiron overload, causing liver injury, after a total of six blood transfusions: fourintrauterine and 2 post-natal transfusion therapies. Intravenous Deferoxaminetreatment was started at the age of 45 days due to a ferritin level of 40,000mg/L, progressive rise of liver enzymes, and worsening cholestasis. Treatmentresulted in marked reduction in ferritin level (down to 829 mg/L at the ageof 6 months), significant improvement in the liver enzymes, and resolutionof cholestasis

🔖

Cite This Article

AHMAD, F. K., ALADILY, T., AHMAD, O. K., BADRAN, E. F. (2018). Chelation therapy for secondary neonatal iron over load: Lessons learned from rhesus hemolytic disease. Turkish Journal of Pediatrics, Cilt: 60 - Sayı: 3, 335–339. https://ajindex.com/articles/412139

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Aygun C, Tekinalp G, Gurgey A. Increased fetal iron load in rhesus hemolytic disease. Pediatr Hematol Oncol 2004; 21: 329-333
  2. Craparo FJ, Bonati F, Gementi P, Nicolini U. The effects of serial intravascular transfusions in ascitic/ hydropic RhD-alloimmunized fetuses. Ultrasound Obstet Gynecol 2005; 25: 144-148
  3. Smits-Wintjens VE, Rath ME, Lindenburg IT, et al. Cholestasis in neonates with red cell alloimmune hemolytic disease: Incidence, risk factors and outcome. Neonatology 2012; 101: 306-310
  4. FBadran E, Al-lawama M, Masri A, Al-Amouri I, Al Kazaleh F. Fetal intrauterine transfusion therapy: Neonatal outcomes. J Blood Lymph 2013; 3: 112
  5. Demircioglu F, Caglayan Sozmen S, Yilmaz S, et al. Severe iron overload and hyporegenerative anemia in a case with rhesus hemolytic disease: therapeutic approach to rare complications. Turk J Haematol 2010; 27: 204-208
  6. Sreenan C, Idikio HA, Osiovich H. Successful chelation therapy in a case of neonatal iron overload following intravascular intrauterine transfusion. J Perinatol 2000; 20: 509-512
  7. Yilmaz S, Duman N, Ozer E, et al. A case of rhesus hemolytic disease with hemophagocytosis and severe iron overload due to multiple transfusions. J Pediatr Hematol Oncol 2006; 28: 290-292
  8. Yalaz M, Bilgin BS, Koroglu OA, et al. Desferrioxamine treatment of iron overload secondary to RH isoimmunization and intrauterine transfusion in a newborn infant. Eur J Pediatr 2011; 170: 1457-1460
  9. Fawaz R, Baumann U, Ekong U, et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017; 64:154-168
  10. Feldman AG, Whitington PF. Neonatal hemochromatosis. J Clin Exp Hepatol 2013; 3: 313-320
  11. Botzenhardt S, Li N, Chan EW, Sing CW, Wong IC, Neubert A. Safety profiles of iron chelators in young patients with haemoglobinopathies. Eur J Haematol 2017; 98: 198-217
  12. Mobarra N, Shanaki M, Ehteram H, et al. A Review on Iron Chelators in Treatment of Iron Overload Syndromes. Int J Hematol Oncol Stem Cell Res 2016; 10: 239-247
  13. Taher AT, Porter JB, Kattamis A, Viprakasit V, Cappellini MD. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusiondependent thalassemia syndromes. Drug